Investors

Taking offline-first receiving beyond its first laboratory.

LotWarden was designed and proven at a working pathology receiving bench and is raising seed capital to reach accredited laboratories more widely. This page is the short version; the investor brief, with figures, is available on request.

The problem

Every accredited lab receives stock the same way, and it is the wrong way.

Reagents, calibrators and controls arrive on paper dockets. Someone transcribes each line into a controlled workbook, checks a separate register if they remember to, and reconstructs the trail by hand when a recall or an assessment demands it. The record that every assessment traces back to is the least automated record in the building.

The obvious fix, a cloud system, is the one most laboratories cannot adopt. Delivery data is confidential, hospital networks are locked down, and the controlled logs are Excel workbooks with years of validation behind them. Any system that asks the lab to change its system of record, or to send data off-site, stalls at IT and quality.

The product

LotWarden is built the other way round. It runs from a folder, only on the PCs a site nominates, never opens a network connection, and writes into the lab's own workbooks through Excel. It reads any supplier's docket after being taught from one clean copy, checks every lot against the acceptance register, builds the investigation worklist, and produces the NATA or ISO 9001 assessment pack in a minute. Every action is hash-chained in an audit log that IT can verify in ten minutes.

Nothing to install, nothing to migrate, nothing leaves the building. That is the whole go-to-market: a product a quality manager can champion and an IT department cannot object to.

1working siteDesigned and proven at a receiving bench

A site edition in use, with departments covering Chemistry, Haematology, Serology and Microbiology workflows.

447/ 447Release checks passing

A validation dossier per build, hash-verified distribution, hash-chained audit trail.

0network callsEnforced at socket level

The compliance story is the security story is the sales story.

100%ownedIndependent IP

Independently designed and developed; personal IP used under licence, with a complete version-controlled history.

Why now

Three things line up.

ISO 15189:2022 is the current standard

Laboratories are being assessed against the 2022 revision, and reception records, acceptance before use and software validation are exactly where findings land. LotWarden was built against those clauses from the start.

Security posture is now a procurement gate

Hospital and pathology networks are refusing systems that move data off-site. An offline-by-design product with a ten-minute proof clears a gate that cloud competitors cannot.

The wedge is small and repeatable

One bench, one nominated PC, one folder, three months to evaluate. No integration project, no data migration, no procurement committee for the pilot. Expansion is department by department, then site by site.

Business model

Per-site licences, renewed on a fixed term.

Each site holds a fixed-term authorisation naming its machines. Renewal is the touchpoint that keeps every copy current, and the moment revenue recurs. Evaluations run on three-month access codes.

  • 1Reach the next laboratories.Walkthroughs, evaluations and site editions for the first cohort of accredited labs beyond the founding site.
  • 2Harden and certify.Code signing, an independent security review of the network guard and request layer, and the documentation IT departments ask for.
  • 3Widen the reader.More supplier layouts and label formats taught out of the box, scored against the answer-key corpus before every release.
  • 4Keep the founder building.The product exists because one person built it at the bench. Funding keeps that person on it full time.

What the investor brief contains

  • The raise, the instrument and the use of funds in detail.
  • Market sizing for accredited laboratories, starting with NATA-accredited pathology in Australia and the ISO 15189 base beyond it.
  • Pricing, the licence model and the expansion path from department to network.
  • Product roadmap and the validation and change-control process.
  • A recorded walkthrough and, on request, a live one on a machine that has never been online.
Request the investor brief